Michael Ryskin
Stock Analyst at B of A Securities
(1.72)
# 2,939
Out of 4,818 analysts
34
Total ratings
47.83%
Success rate
-6.87%
Average return
Main Sectors:
Stocks Rated by Michael Ryskin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRVI Maravai LifeSciences Holdings | Maintains: Buy | $9 → $8 | $2.08 | +284.62% | 3 | Mar 3, 2025 | |
| TEM Tempus AI | Maintains: Neutral | $54 → $60 | $53.50 | +12.15% | 4 | Mar 3, 2025 | |
| IDXX IDEXX Laboratories | Maintains: Neutral | $475 → $535 | $440.98 | +21.32% | 2 | Feb 4, 2025 | |
| ALGN Align Technology | Maintains: Underperform | $200 → $206 | $184.31 | +11.77% | 6 | Dec 13, 2024 | |
| GH Guardant Health | Maintains: Buy | $28 → $40 | $47.33 | -15.49% | 1 | Jul 18, 2024 | |
| ALIT Alight | Maintains: Buy | $10 → $9.5 | $5.27 | +80.27% | 1 | Jun 25, 2024 | |
| CERT Certara | Maintains: Buy | $27 → $24 | $14.43 | +66.32% | 2 | Aug 15, 2023 | |
| AVTR Avantor | Maintains: Buy | $27 → $24 | $15.44 | +55.44% | 2 | Jul 31, 2023 | |
| ZTS Zoetis | Maintains: Buy | $225 → $180 | $152.30 | +18.19% | 7 | Nov 4, 2022 | |
| RXRX Recursion Pharmaceuticals | Downgrades: Neutral | n/a | $5.75 | - | 2 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $80 → $52 | $26.15 | +98.85% | 2 | Nov 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $17 → $10 | $3.20 | +212.50% | 2 | Nov 10, 2021 |
Maravai LifeSciences Holdings
Mar 3, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $2.08
Upside: +284.62%
Tempus AI
Mar 3, 2025
Maintains: Neutral
Price Target: $54 → $60
Current: $53.50
Upside: +12.15%
IDEXX Laboratories
Feb 4, 2025
Maintains: Neutral
Price Target: $475 → $535
Current: $440.98
Upside: +21.32%
Align Technology
Dec 13, 2024
Maintains: Underperform
Price Target: $200 → $206
Current: $184.31
Upside: +11.77%
Guardant Health
Jul 18, 2024
Maintains: Buy
Price Target: $28 → $40
Current: $47.33
Upside: -15.49%
Alight
Jun 25, 2024
Maintains: Buy
Price Target: $10 → $9.5
Current: $5.27
Upside: +80.27%
Certara
Aug 15, 2023
Maintains: Buy
Price Target: $27 → $24
Current: $14.43
Upside: +66.32%
Avantor
Jul 31, 2023
Maintains: Buy
Price Target: $27 → $24
Current: $15.44
Upside: +55.44%
Zoetis
Nov 4, 2022
Maintains: Buy
Price Target: $225 → $180
Current: $152.30
Upside: +18.19%
Recursion Pharmaceuticals
Apr 18, 2022
Downgrades: Neutral
Price Target: n/a
Current: $5.75
Upside: -
Nov 11, 2021
Downgrades: Neutral
Price Target: $80 → $52
Current: $26.15
Upside: +98.85%
Nov 10, 2021
Downgrades: Underperform
Price Target: $17 → $10
Current: $3.20
Upside: +212.50%